Great Point Partners’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Great Point Partners’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-595,473	Closed	-$25.8M	–	41
2020 Q4	$25.8M	Sell	595,473 -60,203	-9%	-$2.97M	4.19%	12
2020 Q3	$36.2M	Buy	655,676 +113,476	+21%	+$7.21M	3.25%	13
2020 Q2	$34.2M	Buy	+542,200	New	+$37.2M	2.74%	14
2019 Q2	–	Sell	-1,180,000	Closed	-$62.5M	–	45
2019 Q1	$62.5M	Hold	1,180,000	–	–	6.18%	3
2018 Q4	$48.4M	Buy	+1,180,000	New	+$44.2M	6.12%	3
2018 Q3	–	Sell	-770,400	Closed	-$34.8M	–	40
2018 Q2	$34.8M	Buy	770,400 +33,769	+5%	+$1.54M	4.83%	8
2018 Q1	$35.6M	Sell	736,631 -66,574	-8%	-$3.71M	5.28%	8
2017 Q4	$31.6M	Buy	803,205 +242,707	+43%	+$9.06M	5.39%	5
2017 Q3	$17.4M	Buy	560,498 +305,098	+119%	+$8.58M	3.39%	13
2017 Q2	$6.99M	Sell	255,400 -44,600	-15%	-$1.33M	1.25%	26
2017 Q1	$11.1M	Sell	300,000 -700,000	-70%	-$17.6M	2.2%	17
2016 Q4	$14.4M	Buy	+1,000,000	New	+$17.6M	2.97%	16

Other funds holding GBT

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Great Point Partners's GBT Position: Q1 2021 in Review

Great Point Partners sold out of Global Blood Therapeutics, Inc. (GBT) in Q1 2021, closing a stake of 595,473 shares — an estimated $25.8M sold.

Great Point Partners first reported a position in GBT in Q4 2016 and held it in 12 quarters. The position peaked at $62.5M in Q1 2019. 214 funds tracked by Wall St. Rank hold GBT as of Q1 2021.

Great Point Partners reported no remaining Global Blood Therapeutics, Inc. position as of Q1 2021 after selling out during the quarter.
Great Point Partners sold 595,473 Global Blood Therapeutics, Inc. shares in Q1 2021, an estimated $25.8M.
Great Point Partners first reported a position in Global Blood Therapeutics, Inc. in Q4 2016 and held it in 12 quarters.
Great Point Partners's Global Blood Therapeutics, Inc. position peaked at $62.5M in Q1 2019.
214 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q1 2021.

Based on Great Point Partners's 13F filing for Q1 2021, filed 17 May 2021.